Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026

Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with...

Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Fineline Cube May 12, 2026

China’s National Medical Products Administration (NMPA) announced the release of the 105th batch of reference...

Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026

China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based...

Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the...

Company Deals

Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market

Fineline Cube May 12, 2026

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc.,...

Company Deals

Hybio Pharmaceutical Licenses GLP-1 Copycats to MCG Pharma for Exclusive Turkish Commercialization

Fineline Cube May 12, 2026

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced a strategic licensing agreement with MCG Pharma, the...

Company Deals

Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh

Fineline Cube May 12, 2026

Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the...

Others

Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China

Fineline Cube May 12, 2026

Cue Biopharma Inc. (NASDAQ: CUE) announced an exclusive licensing agreement with Ascendant Health Sciences Ltd.,...

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026

Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology...

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership...

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received a second Breakthrough Therapy Designation...

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026

Amoy Diagnostics Co., Ltd. (SHE: 300685) announced in collaboration with Japanese partners Riken Genesis Co.,...

Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Fineline Cube May 12, 2026

CanSino Biologics Inc. (HKG: 6185) announced that China’s National Medical Products Administration (NMPA) has included...

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Fineline Cube May 11, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026

Starna Therapeutics, a clinical-stage mRNA drug developer based in Suzhou, announced the completion of a...

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has secured two additional indication approvals from...

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance...

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Fineline Cube May 11, 2026

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of MicroPort Scientific Corp (HKG: 0853),...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Fineline Cube May 11, 2026

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its B7-H3-targeted antibody-drug conjugate (ADC) HS-20093...

Company Drug

CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion

Fineline Cube May 11, 2026

CStone Pharmaceuticals (HKG: 2616) announced the first batch manufacturing and release of its Gavreto (pralsetinib...

Posts pagination

1 … 26 27 28 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.